Needham analyst Quinn Bolton reiterates Intel (NASDAQ:INTC) with a Buy and maintains $32 price target.
Arcturus Therapeutics’ Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside
Canaccord Genuity has initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), a player in the genetic medicine space.